Lonza and Cryoport, Inc. have partnered in the cell and gene therapy field and across Lonza’s ‘vein-to-vein’ delivery network. Lonza has selected Cryoport as its preferred partner in the transport and delivery of patient tissues on a global basis. Lonza and Cryoport will work to remove the supply chain hurdles faced by developers of personalized therapeutics, including autologous therapies, matched-allogeneic therapies, and personalized cancer vaccines, as they prepare for the ...